A simple and robust automated kinase profiling platform using luminescent ADP accumulation technology

Assay and Drug Development Technologies

Volumn 7, Issue 6, 2009, Pages 573-584

  Larson, Brad ^a   Banks, Peter ^a   Zegzouti, Hicham ^b   Goueli, Said A ^b  

^a Bio Tek Instruments Incorporated   (United States)

^b PROMEGA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; REAGENT; STAUROSPORINE; WORTMANNIN;

ARTICLE; AUTOMATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME MECHANISM; ENZYME SUBSTRATE; IC 50; INSTRUMENTATION; LUMINESCENCE; PROTEIN FAMILY; SCREENING; SENSITIVITY ANALYSIS; TECHNOLOGY; TITRIMETRY; VALIDITY;

ADENOSINE DIPHOSPHATE; CHEMISTRY TECHNIQUES, ANALYTICAL; LUMINESCENT MEASUREMENTS; PHOSPHOTRANSFERASES; PROTEIN INTERACTION MAPPING; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 76449102001     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2009.0216     Document Type: Article

References (27)

1. Zhang J, Yang PL, Gray NS: Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39.
2. Jia Y, Quinn CM, Kwak S, Talanian RV: Current in vitro kinase assay technologies: the quest for a universal format. Curr Drug Discov Technol 2008;5:59-69.
3. Hong L, Quinn CM, Jia Y: Evaluating the utility of the HTRF Transcreener ADP assay technology: a comparison with the standard HTRF assay technology. Anal Biochem 2009;391:31-38.
4. Rodems SM, Hamman BD, Lin C, Zhao J, Shah S, Heidary D, et al.: A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases. Assay Drug Dev Technol 2002;1:9-19.
5. Zegzouti H, Zdanovskaia M, Hsiao K, Goueli SA: ADP-Glo: A bioluminescent and homogenous ADP monitoring assay for kinases. Assay Drug Dev Technol 2009; Submitted.
6. Auld DS, Zhang Y-Q, Southall NT, Rai G, Landsman M, Maclure J, et al.: A Basis for reduced chemical library inhibition of firefl y luciferase obtained from directed evolution. J Med Chem 2009;52:1450-1458.
7. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al.: NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-16647.
8. Marais RM, Parker PJ: Purification and characterisation of bovine brain protein kinase C isotypes alpha, beta and gamma. Eur J Biochem 1989;182:129-137.
9. Gamm DM, Baude EJ, Uhler MD: The major catalytic subunit isoforms of cAMPdependent protein kinase have distinct biochemical properties in vitro and in vivo. J Biol Chem 1996;271:15736-15742.
10. Knight ZA, Chiang GG, Alaimo PJ, Kenski DM, Ho CB, Coan K, et al.: Isoformspecific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem 2004;12:4749-4759.
11. Boerner RJ, Barker SC, Knight WB: Kinetic mechanisms of the forward and reverse pp60c-src tyrosine kinase reactions. Biochemistry 1995;34:16419-16423.
12. Isakov N, Wange RL, Watts JD, Aebersold R, Samelson LE: Purification and characterization of human ZAP-70 protein-tyrosine kinase from a baculovirus expression system. J Biol Chem 1996;271:15753-15761.
13. Knight ZA, Shokat KM: Features of selective kinase inhibitors. Chem Biol 2005;12:621-637.
14. Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, Jones RE, et al.: Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 2005;385:399-408.
15. Domin J, Pages F, Volinia S, Rittenhouse SE, Zvelebil MJ, Stein RC, et al.: Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem J 1997;326(Pt 1):139-147.
16. Latour S, Chow LM, Veillette A: Differential intrinsic enzymatic activity of Syk and Zap-70 protein-tyrosine kinases. J Biol Chem 1996;271:22782-22790.
17. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
18. Kerman K, Chikae M, Yamamura S, Tamiya E: Gold nanoparticle-based electrochemical detection of protein phosphorylation. Anal Chim Acta 2007;588:26-33. (Pubitemid 46402910)
19. Jin L, Pluskey S, Petrella EC, Cantin SM, Gorga JC, Rynkiewicz MJ, et al.: The three-dimensional structure of the ZAP-70 kinase domain in complex with staurosporine: implications for the design of selective inhibitors. J Biol Chem 2004;279:42818-42825.
20. Kast R, Schirok H, Figueroa-Perez S, Mittendorf J, Gnoth MJ, Apeler H, et al.: Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase. Br J Pharmacol 2007;152:1070-1080.
21. Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, et al.: Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Bioorg Med Chem Lett 2005;15:905-909.
22. Boldyreff B, Rasmussen TL, Jensen HH, Cloutier A, Beaudet L, Roby P, et al.: Expression and Purification of PI3 kinase alpha and development of an ATP depletion and an alphascreen PI3 kinase activity assay. J Biomol Screen 2008;13:1035-1040.
23. Ruegg UT, Burgess GM: Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol Sci 1989;10:218-220.
24. Prade L, Engh RA, Girod A, Kinzel V, Huber R, Bossemeyer D: Staurosporineinduced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. Structure 1997;5:1627-1637.
25. Fuchikami K, Togame H, Sagara A, Satoh T, Gantner F, Bacon KB, et al.: A versatile high-throughput screen for inhibitors of lipid kinase activity: development of an immobilized phospholipid plate assay for phosphoinositide 3-kinase gamma. J Biomol Screen 2002;7:441-450.
26. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, et al.: Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 2000;6:909-919.
27. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, Pirola L, Vanhaesebroeck B, Waterfield MD, et al.: Wortmannin inactivates phosphoinositide 3-kinase by covalent modifi cation of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 1996;16:1722-1733.